Results 291 to 300 of about 378,224 (340)

Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy. [PDF]

Oncologist
Yazgan SC, Kayaş K, Arslan Ç, Kapar C, Öztekin Ş, Ceylan F, Bölek H, Elboğa U, Ateş Ö, Tural D, Kuş T, Şendur MAN, Yekedüz E, Küçük NÖ, Çıngı Özdemir E, Ürün Y.   +15 more
europepmc   +1 more source

Renal cancer survival and use of 5alpha-reductase inhibitors or androgen deprivation therapy. [PDF]

BMC Urol
Lipponen O, Pöyhönen A, Kotsar A, Veitonmäki T, Tammela TL, Sunela K, Murtola TJ.   +6 more
europepmc   +1 more source

A branching bivariate weibull distribution model for evaluating exosomes in androgen-deprived agency in the presence of prostate cancer. [PDF]

Sci Rep
Shanmugavalli M, Jenvi Ignatia KM, D MJ, Kumar R, Bishoyi AK, Renuka Jyothi S, Channi HK, Bhowmik A, Lozanović J.   +8 more
europepmc   +1 more source

Downregulated androgen receptor expression in preputial tissues of children with hypospadias. [PDF]

Front Pediatr
Yang Z, Zhang P, Zhang T, Yin J, Zhou G, Zhao W, Chen P, Li J, Li S.   +8 more
europepmc   +1 more source

Hyperandrogenism in polycystic ovary syndrome augments Estrogen synthesis through AR-FOXL2-mediated activation of the aromatase gene in granulosa cells. [PDF]

J Ovarian Res
Tsai YR, Liao YN, Tsai CJ, Lee YA, Hsia SM, Lan KC, Kang HY.   +6 more
europepmc   +1 more source

Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer. [PDF]

Oncogene
Chukhu M, Dahiya UR, Heemers HV.
europepmc   +1 more source